AM
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Uncovering a Genetic Polymorphism Located in Huntingtin Associated Protein 1 in Modulation of Central Pain Sensitization Signaling Pathways | Frontiers in neuroscience | 2022 | 404 | 74 | |||
Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity | British journal of pharmacology | 2021 | 312 | 129 | |||
Exploration du rôle de la modulation GABAergique dans la transmission de la douleur chez l'homme : Effet du modulateur allostérique GABAA N-desméthylclobazam sur la sensibilisation centrale; étude pharmacodynamique et pharmacocinétique chez le volontaire sain | 2021 | 322 | 2 | ||||
GABAergic modulation of secondary hyperalgesia: A randomized controlled 4-way crossover trial with the α2-subunit preferring GABA positive allosteric modulator, N-desmethyl-clobazam in healthy volunteers | European Journal of Pain | 2020 | 249 | 1 | |||
Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial | Clinical Microbiology and Infection | 2020 | 318 | 167 | |||
Impact of CYP2D6 functional allelic variations on phenoconversion and drug-drug interactions | Clinical Pharmacology and Therapeutics | 2017 | 485 | 5 | |||
The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia | Neuropharmacology | 2016 | 580 | 298 | |||
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report | The New England journal of medicine | 2016 | 905 | 262 | |||
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients | Multiple sclerosis | 2015 | 637 | 1 | |||
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial | Lancet. Infectious diseases | 2015 | 686 | 0 | |||
P-glycoprotein: a clue to vitamin K antagonist stabilization | Pharmacogenomics | 2015 | 691 | 0 | |||
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up | Journal of neuroimmunology | 2015 | 592 | 1 | |||
GABAergic modulation in central sensitization in humans: a randomized placebo-controlled pharmacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers | Pain | 2015 | 617 | 3 | |||
Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial | Pain physician | 2013 | 615 | 1,073 | |||
Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment | Pharmacogenomics | 2013 | 674 | 0 |